Premium
Glucocorticosteroids in Renal Transplantation
Author(s) -
HAYRY P.,
AHONEN J.,
KOCK B.,
EKLUND B.,
KAUSTE A.,
KOSKIMIES S.,
WILLEBRAND E.
Publication year - 1984
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.1984.tb00922.x
Subject(s) - methylprednisolone , medicine , inflammation , steroid , transplantation , urology , hormone
In a previous clinical trial we demonstrated that. by increasing the postoperative administration of methylprednisolone from 1.0 to 3.5 mg/kg/day. ihe onset of the first inflammatory rejection episode was significantly delayed and the size of the inflammation was reduced. The ‘high initial’ steroid treatment specifically depleted blast cells and macrophages from the in situ inflammatory infiltraie. In ihis trial we demonstrate that the ‘high initial’ glueocorticosteroid administration significantly improves 1‐year cadaver allograft survival from 44% to 68% (P = 0.00.3) without increasing the number of complications. Although the ‘high initial’ steroid administration only partially overcomes the impact of HLA‐AB incompatibility, it seems to overcome entirely the impact of absence of blood transfusions. The ‘high initial’ steroid administration also makes the first episodes of inflammation easier to overcome: less steroids are needed to counteract the first rejection, and, as a consequence, only 30% more steroids were used in the ‘high initial’ versus the ‘low intial’ steroid programme.